Merck & Co. agreed to pay $100 million in February 2014 to settle roughly 3,800 claims from women who developed blood clots after using NuvaRing, the company’s vaginal contraceptive ring. Individual payouts averaged approximately $58,000 to $60,000 per person, though actual amounts varied based on injury severity and other case-specific factors. The settlement resolved litigation that had been consolidated in the U.S. District Court for the Eastern District of Missouri under MDL No.
1964, along with additional state court claims filed in New Jersey and Missouri. The lawsuits centered on allegations that Merck failed to adequately warn women about the elevated blood clot risks associated with NuvaRing’s active ingredient, etonogestrel, a desogestrel-class progestin. A landmark 2012 Danish study of 1.6 million women found that NuvaRing users had a 6.5 times increased risk of venous thrombosis compared to women not using hormonal contraception. For the women who suffered deep vein thrombosis, pulmonary embolism, or stroke, the settlement offered compensation but left many feeling the amount fell short of their losses. This article covers the full scope of the litigation, the blood clot risks that drove it, who qualified for compensation, and why no new NuvaRing lawsuits are being accepted today.
Table of Contents
- How Did the NuvaRing Blood Clot Lawsuit Settlement Come Together?
- What Blood Clot Risks Made NuvaRing So Controversial?
- What Types of Injuries Did NuvaRing Plaintiffs Suffer?
- How Did the Settlement Compensation Compare to Other Contraceptive Lawsuits?
- Why Are No Attorneys Accepting New NuvaRing Cases?
- What Role Did the FDA Play in the NuvaRing Controversy?
- Lessons From the NuvaRing Litigation for Future Contraceptive Cases
- Conclusion
- Frequently Asked Questions
How Did the NuvaRing Blood Clot Lawsuit Settlement Come Together?
The NuvaRing litigation built slowly over several years before reaching critical mass. Since the device’s introduction in 2001, the FDA received nearly 1,000 complaints about blood clots potentially caused by the ring. Individual lawsuits began trickling in during the mid-2000s, and by 2008, enough cases had accumulated that the Judicial Panel on Multidistrict Litigation consolidated federal claims into MDL No. 1964 in the Eastern District of Missouri. State court claims proceeded in parallel in New Jersey and Missouri courts. Merck initially fought the cases aggressively, and several bellwether trials were scheduled to test the strength of plaintiffs’ evidence before juries.
The $100 million settlement, announced in February 2014 and finalized in June of that year, resolved all pending claims across both the federal MDL and state courts. Compensation was distributed through a tiered system rather than an equal split, meaning a woman who suffered a pulmonary embolism requiring hospitalization received substantially more than someone with a treatable deep vein thrombosis. Compare this to the Yaz/Yasmin blood clot settlement, where Bayer paid roughly $2 billion to resolve approximately 10,000 claims at a higher per-claimant average, reflecting the larger plaintiff pool and broader publicity around that litigation. The settlement did not require Merck to admit fault or pull NuvaRing from the market. This is standard in pharmaceutical mass tort settlements and often frustrates plaintiffs who feel the outcome prioritizes corporate interests over public safety. Still, the resolution brought closure to thousands of women who had spent years in litigation while dealing with the physical aftermath of blood clots.
What Blood Clot Risks Made NuvaRing So Controversial?
All combined hormonal contraceptives carry some blood clot risk, but the data on NuvaRing pointed to a risk profile that exceeded many comparable options. NuvaRing users face a risk of 3 to 12 blood clots per 10,000 women-years, compared to 1 to 5 per 10,000 for women not using hormonal contraception. That range matters because it means the risk could be as much as twelve times the baseline rate in some populations, a gap that critics argued Merck downplayed in its marketing materials. The 2012 Danish study became a cornerstone of the plaintiffs’ case. Researchers tracked 1.6 million women and found that NuvaRing users had roughly twice the risk of venous thrombosis compared to women using oral contraceptives containing levonorgestrel, one of the older and better-studied progestins. The study also documented a 2.5 times increased relative risk of thrombotic stroke compared to nonuse, with strokes occurring as early as two weeks after a woman began using the ring.
That last finding was particularly alarming because it suggested some women never had time to recognize warning signs before suffering a serious event. However, these statistics require context. If a woman has no additional risk factors, meaning she is under 35, a non-smoker, not obese, and has no family history of clotting disorders, her absolute risk remains relatively low even with NuvaRing. The danger escalates sharply when risk factors stack. A 32-year-old smoker with a previously undiagnosed Factor V Leiden mutation faces a dramatically different risk calculus than a healthy 25-year-old. The lawsuits argued that Merck should have made these compounding risks far more explicit in its patient-facing materials.
What Types of Injuries Did NuvaRing Plaintiffs Suffer?
The blood clots linked to NuvaRing were not abstract statistical risks for the women who filed suit. Many experienced deep vein thrombosis, typically in the legs, where a clot forms in a deep vein and causes swelling, pain, and potentially permanent damage to the vein’s valves. Others developed pulmonary embolism, a life-threatening condition where a clot travels to the lungs. Some plaintiffs suffered thrombotic strokes, with effects ranging from temporary weakness to permanent disability. One frequently cited case involved a young woman in her twenties who developed a pulmonary embolism within months of starting NuvaRing. She had no prior clotting history and no traditional risk factors.
Her experience mirrored a pattern that emerged across the litigation: otherwise healthy young women developing serious clotting events that their doctors initially struggled to connect to their contraceptive. The delay in diagnosis sometimes worsened outcomes, because neither the patients nor their physicians immediately suspected the ring. The tiered settlement system attempted to account for this range of outcomes. Women who suffered fatal clotting events or permanent disabilities received payouts at the higher end, while those with less severe outcomes received less. Families who lost loved ones to NuvaRing-related blood clots also participated in the settlement, though no dollar amount could replace what they lost. The structure acknowledged a basic reality of mass tort litigation: injuries exist on a spectrum, and a single settlement figure cannot fairly address every case.
How Did the Settlement Compensation Compare to Other Contraceptive Lawsuits?
The $100 million NuvaRing settlement, averaging $58,000 to $60,000 per claimant, was modest by pharmaceutical mass tort standards. For comparison, Bayer’s Yaz and Yasmin settlements totaled roughly $2 billion across approximately 10,000 claims, yielding higher average payouts per plaintiff. The Ortho Evra birth control patch litigation also produced settlements with generally higher per-claimant values. These differences reflected several factors, including the number of plaintiffs, severity distribution of injuries, and the strength of the scientific evidence linking each product to harm. One tradeoff plaintiffs faced was the classic mass tort dilemma: settle for a guaranteed but potentially underwhelming amount, or continue litigating with the chance of a larger verdict but also the risk of losing entirely.
Merck had substantial legal resources, and pharmaceutical companies have historically shown willingness to take cases to trial when they believe the evidence is defensible. The $100 million offer came before any jury verdict, meaning plaintiffs had no trial outcome to use as leverage. Many attorneys advised their clients to accept the settlement rather than gamble on unpredictable jury decisions. For the women who accepted, the payout often covered medical bills and some lost wages but rarely felt like full compensation for the experience of a life-threatening medical event. Several plaintiffs publicly expressed frustration that the per-person average was less than many personal injury settlements for car accidents or slip-and-fall cases, despite the severity of their injuries. The settlement also did not cover future medical costs for women who developed chronic conditions like post-thrombotic syndrome as a result of their blood clots.
Why Are No Attorneys Accepting New NuvaRing Cases?
The NuvaRing litigation is closed. No new cases have been filed since approximately November 2022, and as of January 2026, no attorneys are currently accepting new NuvaRing lawsuits, according to Drugwatch. The statute of limitations has expired for most potential plaintiffs, and the MDL was effectively resolved years ago. Women who believe they suffered blood clots from NuvaRing but never filed suit have almost certainly missed their window. This does not mean NuvaRing is considered safe. The product remains on the market with FDA approval, and its label now includes clearer warnings about blood clot risks.
The FDA label specifically notes that the risk of venous thromboembolism is highest during the first year of use and when restarting the ring after a break of four or more weeks. It also acknowledges that the risk of blood clots may be greater with the type of progestin in NuvaRing, etonogestrel, which belongs to the desogestrel class, than with some other progestins found in certain low-dose pills. Women currently using NuvaRing should not interpret the closed litigation as a signal that the product is risk-free. The settlement resolved legal claims but did not change the underlying pharmacology. Anyone experiencing symptoms like sudden leg swelling, unexplained shortness of breath, or sudden severe headache while using NuvaRing should seek immediate medical attention. These symptoms can indicate a blood clot that requires emergency treatment regardless of whether a lawsuit is viable.
What Role Did the FDA Play in the NuvaRing Controversy?
The FDA’s handling of NuvaRing drew criticism from both patient advocates and some members of Congress. NuvaRing contains etonogestrel and ethinyl estradiol, delivering 0.120 mg and 0.015 mg per day respectively. When the agency approved the device, its label included standard blood clot warnings common to all combined hormonal contraceptives, but critics argued these warnings were too generic and failed to highlight the specific risks associated with etonogestrel.
The nearly 1,000 adverse event reports the FDA received about NuvaRing-related blood clots raised questions about whether the agency should have acted sooner to require stronger warnings or additional studies. The FDA ultimately updated the NuvaRing label to include more specific language about the elevated clot risk associated with desogestrel-class progestins, but this update came after much of the litigation had already played out. For the women who developed blood clots before these label changes, the updated warnings arrived too late to influence their prescribing decisions.
Lessons From the NuvaRing Litigation for Future Contraceptive Cases
The NuvaRing settlement established several precedents that continue to shape how pharmaceutical blood clot cases are litigated. It demonstrated that even with relatively modest individual payouts, consolidated litigation can force manufacturers to confront safety data they might otherwise minimize. The Danish study’s role in the case also highlighted the growing importance of large-scale epidemiological research in establishing causation, a standard that has become increasingly central in pharmaceutical mass torts.
Looking ahead, women considering hormonal contraceptives have more information available than those who started NuvaRing in the early 2000s. Prescribers are now more attuned to progestin-specific clot risks, and patients can access comparative safety data that was harder to find two decades ago. The NuvaRing litigation, for all its limitations, contributed to a broader shift toward transparency in contraceptive risk communication, a shift that benefits women making these decisions today even though it came at a significant cost to those who were harmed before the risks were widely understood.
Conclusion
The NuvaRing blood clot lawsuit settlement stands as a significant but imperfect resolution to a pharmaceutical safety crisis that affected thousands of women. Merck’s $100 million payout resolved approximately 3,800 claims, with individual compensation averaging $58,000 to $60,000 depending on injury severity. The litigation brought critical attention to the elevated blood clot risks associated with desogestrel-class progestins, and the 2012 Danish study’s finding of a 6.5 times increased thrombosis risk became a defining piece of evidence in the case.
The litigation is now closed, and no attorneys are accepting new NuvaRing cases as of 2026. NuvaRing remains FDA-approved and available, with updated labeling that more clearly communicates blood clot risks. Women currently using or considering the device should discuss their individual risk factors with their healthcare provider, paying particular attention to smoking status, age, weight, family clotting history, and any planned periods of immobility such as surgery or long flights. The NuvaRing story is a reminder that FDA approval does not mean risk-free, and that the full safety profile of any medication sometimes only becomes clear after millions of women have used it.
Frequently Asked Questions
How much was the NuvaRing settlement worth in total?
Merck agreed to pay $100 million in February 2014 to resolve approximately 3,800 NuvaRing blood clot claims. The settlement was finalized in June 2014.
How much did individual NuvaRing plaintiffs receive?
Individual payouts averaged approximately $58,000 to $60,000, though actual amounts varied based on a tiered system that factored in injury severity and other case-specific metrics. Women with more severe injuries like pulmonary embolism or stroke received higher amounts.
Can I still file a NuvaRing lawsuit?
No. The NuvaRing litigation is closed, with no new cases filed since approximately November 2022. As of January 2026, no attorneys are accepting new NuvaRing lawsuits. The statute of limitations has expired for most potential plaintiffs.
Is NuvaRing still on the market?
Yes. NuvaRing remains FDA-approved and available for prescription. Its label now includes more specific warnings about blood clot risks associated with etonogestrel, a desogestrel-class progestin.
What are the blood clot warning signs for NuvaRing users?
Symptoms to watch for include sudden leg swelling or pain, unexplained shortness of breath, chest pain, sudden severe headache, and vision changes. These can indicate deep vein thrombosis, pulmonary embolism, or stroke. The risk is highest during the first year of use and when restarting after a break of four or more weeks.
How does NuvaRing’s blood clot risk compare to other birth control?
NuvaRing users face a risk of 3 to 12 blood clots per 10,000 women-years, compared to 1 to 5 per 10,000 for non-users of hormonal contraception. The 2012 Danish study found NuvaRing carried roughly twice the clot risk of oral contraceptives containing levonorgestrel.